The latest data point for Operating ROA in Q4'25 shows ROE at -1.91% and ROA at -0.79%, indicating a downturn in profitability metrics for Pfizer (PFE), while ROIC remains without data for this period. This follows a positive Q3'25 where ROA reached 1.70% and ROIC stood at 2.14%, highlighting a sharp reversal in the final quarter of the fiscal year. Over the period from Q1'23 to Q4'25, ROE and ROA exhibit volatile trends with an overall recovery pattern after initial declines, starting from 5.49% and 2.83% in Q1'23, dipping to negative values like -3.78% for ROE and -1.49% for ROA in Q4'23, then rebounding to peaks of 4.84% for ROE and 2.03% for ROA in Q3'24 before stabilizing around 3-4% in mid-2025 quarters. ROIC mirrors this volatility but shows more pronounced swings, including a severe drop to -132.68% in Q4'24, with data gaps in Q1'25, Q2'25, and Q4'25 limiting full trend visibility; dominant patterns suggest improving capital efficiency post-2023 lows, though the Q4'25 negatives signal potential operational challenges.